Published in Cancer on May 01, 2006
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer (2013) 1.10
Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol (2011) 1.03
Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98
Pathogenesis, diagnosis and management of primary melanoma of the colon. World J Surg Oncol (2011) 0.98
Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. Ann Surg Oncol (2014) 0.79
Posterior mediastinal melanoma causing severe dysphagia: a case report. J Med Case Rep (2008) 0.77
A primary malignant melanoma of the mediastinum with gross surgical view. J Thorac Dis (2016) 0.77
Metastatic malignant melanoma of the inguinal lymph node with unknown primary lesion. Case Rep Med (2015) 0.75
Amelanotic melanoma presenting with cervical lymphadenopathy. BMJ Case Rep (2009) 0.75
Treatment of Regional Metastatic Melanoma of Unknown Primary Origin. Cancers (Basel) (2015) 0.75
Management decisions for nodal metastasis from an unknown primary melanoma. Am J Hematol Oncol (2008) 0.75
The clinical features, treatment, and prognosis of primary mediastinal malignant melanoma: A case report. Medicine (Baltimore) (2017) 0.75
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
A landscape of driver mutations in melanoma. Cell (2012) 12.61
A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med (2013) 9.97
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
A map of rice genome variation reveals the origin of cultivated rice. Nature (2012) 4.92
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med (2011) 4.71
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med (2011) 3.10
Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med (2011) 2.91
Shared frailty models for recurrent events and a terminal event. Biometrics (2004) 2.86
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab (2010) 2.74
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol (2011) 2.23
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol (2004) 2.18
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol (2006) 2.12
Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery (2006) 2.09
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab (2010) 2.09
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer (2012) 2.01
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol (2004) 2.00
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Angiosarcoma of the breast. Cancer (2005) 1.98
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol (2007) 1.92
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 1.89
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg (2009) 1.89
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer (2007) 1.88
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood (2007) 1.87
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol (2006) 1.85
Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg (2005) 1.84
The learning curve in pancreatic surgery. Surgery (2007) 1.84
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol (2012) 1.82
Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg (2003) 1.81
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer (2008) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer (2010) 1.80
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer (2008) 1.77
Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol (2005) 1.76
Femtomolar transition state analogue inhibitors of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli. J Biol Chem (2005) 1.76
Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol (2003) 1.74
Transition state structure of 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues. Biochemistry (2005) 1.73
Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol (2008) 1.71